UBS Group’s Medicines Co MDCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,277,342
Closed -$108M 8868
2019
Q4
$108M Buy
1,277,342
+754,143
+144% +$50.3M 0.04% 430
2019
Q3
$26.2M Buy
523,199
+301,105
+136% +$12M 0.01% 1058
2019
Q2
$8.1M Sell
222,094
-285,428
-56% -$9.32M ﹤0.01% 1927
2019
Q1
$14.2M Buy
507,522
+93,855
+23% +$2.21M 0.01% 1399
2018
Q4
$7.92M Buy
413,667
+348,310
+533% +$8.1M ﹤0.01% 1768
2018
Q3
$1.95M Buy
65,357
+17,490
+37% +$659K ﹤0.01% 3242
2018
Q2
$1.76M Buy
47,867
+2,225
+5% +$72.3K ﹤0.01% 3283
2018
Q1
$1.5M Buy
45,642
+4,059
+10% +$127K ﹤0.01% 3362
2017
Q4
$1.14M Sell
41,583
-13,677
-25% -$421K ﹤0.01% 3682
2017
Q3
$2.05M Buy
55,260
+53
+0.1% +$1.95K ﹤0.01% 3111
2017
Q2
$2.1M Buy
55,207
+6,631
+14% +$295K ﹤0.01% 2971
2017
Q1
$2.38M Buy
48,576
+35,012
+258% +$1.6M ﹤0.01% 2784
2016
Q4
$461K Sell
13,564
-126,168
-90% -$4.47M ﹤0.01% 4184
2016
Q3
$5.27M Buy
139,732
+124,214
+800% +$4.68M ﹤0.01% 1972
2016
Q2
$522K Sell
15,518
-616
-4% -$21.7K ﹤0.01% 3852
2016
Q1
$512K Buy
16,134
+8,494
+111% +$277K ﹤0.01% 3762
2015
Q4
$285K Buy
7,640
+103
+1% +$3.89K ﹤0.01% 4393
2015
Q3
$286K Buy
7,537
+2,465
+49% +$86.5K ﹤0.01% 4355
2015
Q2
$145K Sell
5,072
-366
-7% -$10.2K ﹤0.01% 5125
2015
Q1
$152K Buy
5,438
+471
+9% +$13.2K ﹤0.01% 5098
2014
Q4
$138K Buy
+4,967
New +$123K ﹤0.01% 5377

Other funds holding MDCO

UBS Group's MDCO Position: Q1 2020 in Review

UBS Group sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 1,277,342 shares — an estimated $108M sold.

UBS Group first reported a position in MDCO in Q4 2014 and held it in 21 quarters. The position peaked at $108M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • UBS Group reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • UBS Group sold 1,277,342 Medicines Co shares in Q1 2020, an estimated $108M.
  • UBS Group first reported a position in Medicines Co in Q4 2014 and held it in 21 quarters.
  • UBS Group's Medicines Co position peaked at $108M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.